← All trials
NCT05627258
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2022
- Primary completion
- Dec 29, 2023
- Completion date
- Dec 29, 2023
- First posted
- Nov 25, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 40
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.